Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.

Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T.

J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20. No abstract available.

PMID:
23690412
2.

Vemurafenib for relapsed or refractory hairy-cell leukaemia.

Baker H.

Lancet Oncol. 2015 Oct;16(13):e484. doi: 10.1016/S1470-2045(15)00334-4. Epub 2015 Sep 18. No abstract available.

PMID:
26387749
3.

Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.

Munoz J, Schlette E, Kurzrock R.

J Clin Oncol. 2013 Jul 10;31(20):e351-2. doi: 10.1200/JCO.2012.45.7739. Epub 2013 Jun 3. No abstract available.

PMID:
23733763
4.

BRAF inhibition in refractory hairy-cell leukemia.

Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T.

N Engl J Med. 2012 May 24;366(21):2038-40. doi: 10.1056/NEJMc1202124. No abstract available.

5.

Hairy cell leukemia.

Dearden C.

Best Pract Res Clin Haematol. 2015 Dec;28(4):163-5. doi: 10.1016/j.beha.2015.10.021. Epub 2015 Nov 11. No abstract available.

PMID:
26614893
6.

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi F.

J Clin Oncol. 2016 Mar 1;34(7):e57-60. doi: 10.1200/JCO.2013.50.9661. Epub 2014 Jun 30. No abstract available.

PMID:
24982452
7.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS.

N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.

8.

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G.

Haematologica. 2013 Feb;98(2):e20-2. doi: 10.3324/haematol.2012.082404. Epub 2013 Jan 8. No abstract available.

9.

Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.

Vergote V, Dierickx D, Janssens A, Verhoef G, Tousseyn T, Vandenberghe P, Wolter P, Delforge M.

Ann Hematol. 2014 Dec;93(12):2087-9. doi: 10.1007/s00277-014-2104-2. Epub 2014 May 27. No abstract available.

PMID:
24863690
10.

Update on the biology and treatment options for hairy cell leukemia.

Jain P, Pemmaraju N, Ravandi F.

Curr Treat Options Oncol. 2014 Jun;15(2):187-209. doi: 10.1007/s11864-014-0285-5. Review.

11.

Hairy cell leukemia: Past, present and future.

Getta BM, Park JH, Tallman MS.

Best Pract Res Clin Haematol. 2015 Dec;28(4):269-72. doi: 10.1016/j.beha.2015.10.015. Epub 2015 Oct 21. Review.

12.

Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.

Maurer H, Haas P, Wengenmayer T, Lübbert M, Duyster J, Zeiser R.

Ann Hematol. 2014 Aug;93(8):1439-40. doi: 10.1007/s00277-013-1987-7. Epub 2013 Dec 14. No abstract available.

PMID:
24337488
13.

BRAF inhibitor therapy in HCL.

Dietrich S, Zenz T.

Best Pract Res Clin Haematol. 2015 Dec;28(4):246-52. doi: 10.1016/j.beha.2015.10.001. Epub 2015 Oct 20. Review.

PMID:
26614903
14.

[Successful use of vemurafenib in a patient with resistant hairy cell leukemia].

Urnova ES, Al'-Radi LS, Kuz'mina LA, Kariakina AA, Kovrigina AM, Dvirnyk VN, Iakutik IA, Sudarikov AB, Parovichnikova EN, Savchenko VG.

Ter Arkh. 2013;85(7):76-8. Russian.

PMID:
24137951
15.

Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.

Forconi F, Toraldo F, Sozzi E, Amato T, Raspadori D, Lauria F.

Leuk Lymphoma. 2007 Dec;48(12):2441-3. No abstract available.

PMID:
18067021
16.

Hairy cell leukemia: update and current therapeutic approach.

Salam L, Abdel-Wahab O.

Curr Opin Hematol. 2015 Jul;22(4):355-61. doi: 10.1097/MOH.0000000000000154. Review.

PMID:
26049757
17.

New insights in the management of patients with hairy cell leukemia.

Cornet E, Damaj G, Troussard X.

Curr Opin Oncol. 2015 Sep;27(5):371-6. doi: 10.1097/CCO.0000000000000214. Review.

PMID:
26154707
18.

Long-term follow-up after purine analogue therapy in hairy cell leukaemia.

Else M, Dearden CE, Catovsky D.

Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29. doi: 10.1016/j.beha.2015.09.004. Epub 2015 Oct 9. Review.

19.

Historical overview of hairy cell leukemia.

Andritsos LA, Grever MR.

Best Pract Res Clin Haematol. 2015 Dec;28(4):166-74. doi: 10.1016/j.beha.2015.10.018. Epub 2015 Oct 26. Review.

PMID:
26614894
20.

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.

Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T.

Blood. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Epub 2016 Mar 3.

Supplemental Content

Support Center